Table 2.
ACR response rates (%) at study end in RAPID 1 (Week 52), RAPID 2 (Week 24) and FAST4WARD (Week 24) [4–6]
| Study | ACR20 | ACR50 | ACR70 |
|---|---|---|---|
| RAPID 1a,b | |||
| Placebo + MTX Q2 W (n = 199) | 13.6 | 7.6 | 3.5 |
| CZP 200 mg + MTX Q2 W (n = 393) | 53.1, P < 0.001 | 38.0, P < 0.001 | 21.2, P < 0.001 |
| CZP 400 mg + MTX Q2 W (n = 390) | 54.9, P < 0.001 | 39.9, P < 0.001 | 23.2, P < 0.001 |
| RAPID 2a,b | |||
| Placebo + MTX Q2 W (n = 127) | 8.7 | 3.1 | 0.8 |
| CZP 200 mg + MTX Q2 W (n = 246) | 57.3, P < 0.001 | 32.5, P < 0.001 | 15.9, P ≤ 0.01 |
| CZP 400 mg + MTX Q2 W (n = 246) | 57.6, P < 0.001 | 33.1, P < 0.001 | 10.6, P ≤ 0.01 |
| FAST4WARDc,d | |||
| Placebo Q4 W (n = 109) | 9.3 | 3.7 | 0 |
| CZP 400 mg Q4 W (n = 111) | 45.5, P < 0.001 | 22.7, P < 0.001 | 5.5, P ≤ 0.05 |
aITT population: analyses performed using non-responder imputation. bDosing every 2 weeks (Q2 W). cModified ITT population: analyses performed using non-responder imputation. dDosing every 4 weeks (Q4 W). P-values vs placebo plus MTX or placebo alone. ACR20/ACR50/ACR70 responses for the CZP and placebo groups were compared using logistic regression with treatment and geographical region as factors in the RAPID trials or a Cochran–Mantel–Haenszel test stratified by country in the FAST4WARD trial. Details of the statistical analyses are provided in the primary publications for the trials [4–6]. ITT: intention-to-treat.